U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07391670) titled 'A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab' on Jan. 30.
Brief Summary: The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab administration and to evaluate the pharmacokinetics and safety of SC durvalumab + rHu injection in participants with different types of solid tumours (cancers).
Study Start Date: March 31
Study Type: INTERVENTIONAL
Condition:
Solid Tumours
Intervention:
DRUG:...